Breast Cancer | Norton Healthcare

Indication: Breast Cancer

A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal

HER2 Negative

Drug Study

Principal Investigator: Laila Agrawal, M.D.
Norton Cancer Institute

Sponsor: Bristol-Myers Squibb (BMS)

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.